CRISPR Therapeutics AG - Company Profile

Powered by

All the data and insights you need on CRISPR Therapeutics AG in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date CRISPR Therapeutics AG Strategy Report

  • Understand CRISPR Therapeutics AG position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

CRISPR Therapeutics AG: Overview

Select Item

CRISPR Therapeutics AG (CRISPR) is a gene editing company. It focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a gene-editing technology that modifies, deletes, or corrects disease-causing abnormalities at its genetic sources. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells; ex vivo programs in immuno-oncology; in vivo programs targeting the liver and additional in vivo programs targeting other organ systems including muscle and lung. It has research and development operations in Cambridge, Massachusetts, the US and business operations in London, the UK. CRISPR is headquartered in Zug, Switzerland.

 Gain a 360-degree view of CRISPR Therapeutics AG and make more informed decisions for your business Gain a 360-degree view of CRISPR Therapeutics AG and make more informed decisions for your business Find out more
Headquarters Switzerland
Address Baarerstrasse 14, Zug, 6300
Website crisprtx.com
Telephone 41 41 5613279
No of Employees 407
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange CRSP (NASD)
Revenue (2022) $371.2M 30885.5% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 76.4% (2022 vs 2021)
Market Cap* $4.9B
Net Profit Margin (2022) XYZ 99.9% (2022 vs 2021)
* As of and is in US$
View CRISPR Therapeutics AG financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

CRISPR Therapeutics AG premium industry data and analytics

50+

Pipeline Drugs

Identify which of CRISPR Therapeutics AG’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for CRISPR Therapeutics AG’s relevant decision makers and contact details.

40+

Catalyst Calendar

Proactively evaluate CRISPR Therapeutics AG’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

15+

Clinical Trials

Determine CRISPR Therapeutics AG go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Products and Services

Products
Pipeline
Hemoglobinopathies:
Exa-cel: Beta Thalasemia
XYZ
XYZ
XYZ
Understand CRISPR Therapeutics AG portfolio and identify potential areas for collaboration Understand CRISPR Therapeutics AG portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Regulatory Approval In February, the company received conditional marketing authorization to CASGEVY (exagamglogene autotemcel [exa-cel]) from the European Commission.
2023 Regulatory Approval In June, the company and Vertex Pharmaceuticals' Biologics License Applications were accepted by the US FDA for the investigational treatment exagamglogene autotemcel for severe sickle cell disease and transfusion-dependent beta thalassemia.
2023 Contracts/Agreements In March, the company signed a new non-exclusive licensing agreement with Vertex Pharmaceuticals to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D).
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters CRISPR Therapeutics AG Sangamo Therapeutics Inc Poseida Therapeutics Inc Precision Biosciences Inc UniQure NV
Headquarters Switzerland United States of America United States of America United States of America Netherlands
City Zug Richmond San Diego Durham Amsterdam
State/Province - California California North Carolina Noord-Holland
No. of Employees 407 405 327 109 480
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Samarth Kulkarni Chairman; Director; Chief Executive Officer Executive Board 2023 -
Raju Prasad, Ph.D Chief Financial Officer Senior Management 2023 -
Shelby Walker Head - Intellectual Property Senior Management 2018 -
Steve Caffe Head - Regulatory Affairs Senior Management - -
Alex Harding, M.D., M.B.A Head - Business Development Senior Management 2023 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into CRISPR Therapeutics AG key executives to enhance your sales strategy Gain insight into CRISPR Therapeutics AG key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward